Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their ...

Meanwhile, competition is looming. Novartis’s Tabrecta and EMD Serono’s Tepmetko are both approved for treating NSCLC in patients whose tumors have MET exon 14 skipping mutations. Clinical ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but TEPMETKO's once-daily dosing and efficacy profile offer differentiation. TEPMETKO is a kinase inhibitor prescribed for ...

Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta ...

Advt As per industry estimates, Tabrecta recorded sales of USD 126 million in the US market for the year 2023. Capmatinib hydrochloride is indicated for the treatment of adult patients with ...

Natco Pharma has submitted to the U.S. Food and Drug Administration an abbreviated new drug application for a generic version of Novartis’ cancer drug Tabrecta (capmatinib hydrochloride).

The company has submitted an abbreviated new drug application (ANDA) containing a paragraph IV certification with the US Food and Drug Administration (FDA) for the generic version of Novartis' ...

Total royalty revenues, which are primarily comprised of royalties from Novartis for Jakafi and Tabrecta, royalties from Lilly for Olumiant were $126 million, up 9% compared to the first quarter ...

Tabrecta, for non-small-cell lung cancer; and Opzelura, for eczema and vitiligo. “I love Incyte. We built a world-class drug discovery team. But I’d been there for a long time—almost 20 ...